Compare Nuwellis Inc (NUWE) vs Primo Brands Corporation Class A Common Stock (PRMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Primo Brands Corporation Class A Common Stock — how do they compare? Nuwellis Inc trades at $0.55 (market cap $2.00M), while Primo Brands Corporation Class A Common Stock trades at $18.64 (market cap $6.84B). The key difference: Primo Brands Corporation Class A Common Stock is far larger — about 3420× Nuwellis Inc's market cap, and Primo Brands Corporation Class A Common Stock pays a 2.54% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 27 Days and Primo Brands Corporation Class A Common Stock for 0 Days on average.
| NUWE | PRMB | |
|---|---|---|
Market Cap | $2.00M | $6.84B |
Volume | 172,259 | 2,864,594 |
Sector | Health | Consumer Staples |
52-Week High | $146.65 | $25.39 |
52-Week Low | $0.53 | $14.46 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | -$1.72M | $12.17B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.621, down 7.35% today, with a bearish technical signal despite oversold RSI readings. The company shows revenue growth with 2026 revenue reaching $9M, but continues to post significant losses with a -125.63% net income margin. Recent positive developments include strong Aquadex console adoption and expanded pediatric footprint, though cash flow remains negative requiring ongoing financing.
The outlook remains challenging with persistent losses and negative cash flow offset by promising commercial momentum. Investment opportunity hinges on the company's ability to achieve profitability while risks include execution challenges and dependence on financing. Analyst sentiment is mixed with equal buy/hold ratings reflecting the high-risk, high-reward nature of this medical technology stock.
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →
